2020), while other studies suggest that the loss of synapses precedes the loss of neurons, which therefore alters the levels of SNAP‐25 in the preclinical stages (Zhang et al. 2018). More recently, a meta‐analysis has shown that SNAP‐25 levels in CSF differentiated patients with MCI or AD from healthy controls (HC). Furthermore, correlations were found when comparing CSF total tau (t‐tau) and phosphorylated tau (p‐tau) with CSF SNAP‐25 (Liu et al. 2022), highlighting the strong link between tau pathophysiology and synaptic loss. The gene discussed is MAPT; the disease is Alzheimer disease.